Click on headlines below to download research

Progressing towards proof-of-concept data
Herantis Pharma | 06/03/2019

Top-line data from Phase I/II asset CDNF in Parkinson’s disease (PD) is expected in H219; positive efficacy/safety data from this ongoing proof-of-concept…

Innovation at its core
Herantis Pharma | 20/09/2018

Herantis Pharma is focused on the development of innovative regenerative medicines targeting unmet needs. Its two lead assets are cerebral dopamine neurotrophic…